Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Endotrophin is a cleavage product of collagenVIα3 (COL6A3). Here, we explore the relationship between thiazolidinediones (TZDs), endotrophin and cisplatin resistance in the context of a mammary tumour model. COL6A3 levels are increased in response to cisplatin exposure in tumours. Endotrophin, in turn, causes cisplatin resistance. The effects of endotrophin can be bypassed, either through use of COL6 null (COL6(-/-)) mice or by administering TZDs in wild-type mice (leading to a downregulation of endotrophin). Both approaches sensitize tumours to cisplatin through the suppression of endotrophin-induced epithelial-mesenchymal transition. The beneficial effects of TZDs on cisplatin sensitivity are diminished in COL6(-/-) mice, whereas endotrophin(+) tumours are sensitive to the TZD/cisplatin combination. Therefore, the chemosensitization obtained with TZDs is achieved through a downregulation of endotrophin. Treatment with an endotrophin neutralizing antibody in combination with cisplatin completely inhibits tumour growth of tumour allografts. Combined, our data suggest that endotrophin levels are a strong prognostic marker for the effectiveness of the combination therapy of TZDs with cisplatin, and neutralization of endotrophin activity dramatically improves the therapeutic response to combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 2×
“However, an inherent or acquired resistance to cisplatin is a major clinical drawback for patients who relapse after initial favourable responses (Galluzzi et al, 2012).”
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085 · cited 1×
“It is also involved in various physiological processes, such as cell proliferation, angiogenesis, inflammation and lipid partitioning (Tontonoz & Spiegelman, 2008).”
Metabolic Dysregulation and Adipose Tissue Fibrosis: Role of Collagen VI
Khan, T., Muise, E. S., Iyengar, P., Wang, Z. V., Chandalia, M., Abate, N., Zhang, B. B., Bonaldo, P., Chua, S., & Scherer, P. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01300-08 · Cited by 1,053
Self-citationAdipocyte-derived endotrophin promotes malignant tumor progression
Park, J., & Scherer, P. E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63930 · Cited by 350 · cited 9×
“This limits endotrophin secretion to the local tumour microenvironment (Park & Scherer, 2012b).”
InfluentialSelf-citationBurstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228 · cited 1×
“This is consistent with clinical reports that failed to see an impact on the malignancies of epithelial cancer cells (Burstein et al, 2003; Kulke et al, 2002; Smith et al, 2004).”
Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., & Bagnato, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2325 · Cited by 187
Proangiogenic Contribution of Adiponectin toward Mammary Tumor Growth In vivo
Landskroner-Eiger, S., Qian, B., Muise, E. S., Nawrocki, A. R., Berger, J. P., Fine, E. J., Koba, W., Deng, Y., Pollard, J. W., & Scherer, P. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2649 · Cited by 145
Self-citation
Cited by
Fibrosis and adipose tissue dysfunction.
Sun, K., Tordjman, J., Clément, K., & Scherer, P. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.016 · Cited by 960
Self-citationObesity and cancer—mechanisms underlying tumour progression and recurrence
Park, J., Morley, T. S., Kim, M., Clegg, D. J., & Scherer, P. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.94 · Cited by 790
Self-citationNissen, N. I., Karsdal, M., & Willumsen, N. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1110-6 · Cited by 489
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Hernandez-Quiles, M., Broekema, M. F., & Kalkhoven, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624112 · Cited by 433
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382
Metadata
- Authors
- Park, J., Morley, T. S., & Scherer, P. E.
- Venue
- EMBO Molecular Medicine
- Published
- 2013-04-30
- Volume
- 5
- Issue
- 6
- Pages
- 935-948
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2097314802
- Cited by
- 111
- References
- 7
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. https://app.cochat.ai/papers/10.1002/emmm.201202006
- The paper
- Park, J., Morley, T. S., & Scherer, P. E. (2013). Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Molecular Medicine. https://doi.org/10.1002/emmm.201202006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.